The substance is metabolized in the liver, mainly via CYP3A, and in the intestinal wall.
Studies have shown that genetic polymorphisms of genes other than CYP3A5, such as NR1I2[REF][REF] (encoding PXR), also significantly influence the pharmacokinetics of tacrolimus.